CLINICAL TRIAL / NCT06253221

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventional
Active
NCT06253221

Eligibility Details Visit Clinicaltrials.gov

Contact Information

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Eligibility Details

Gender
All

Age Group
12 Years to 17 Years

Accepting Healthy Volunteers
No

Inclusion Criteria: - Diagnosis of HCM - Presence of LVOT obstruction - Presence of symptoms Exclusion Criteria: - Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction - Evidence of LVEF <50% in prior 6 months - Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase) Other protocol-defined Inclusion/Exclusion criteria apply.

CLINICAL TRIAL / NCT06253221

Contact Information

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to &lt; 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Eligibility Details

Related Conditions

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy